agreed - and also hiding in plain sight is the DME indication which based on Fred’s statements is about half the size of wet AMD and sozibercept seems to perform better for this disease.
If BP outright buys out OPT, I think they will need to give a valuation closer to $12-15B. I think more than likely OPT will partner with BP for ex-US rights only.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable